Assessing cardiovascular risk in patients undergoing high dose chemotherapy
Cardiovascular Diagnostic in Assessment of Risk High Dose Chemotherapy and Hematopoietic Cell Transplantation in Patients With Haemoblasts.
This study is testing different heart check-up methods to see if they can help identify patients at risk for heart problems after receiving high dose chemotherapy for blood cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | I.M. Sechenov First Moscow State Medical University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Moscow) |
| Trial ID | NCT05508087 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the use of various cardiological diagnostic tools, including electrocardiography, echocardiography, cardiopulmonary exercise tests, and endothelial function assessment, to predict cardiovascular complications in patients with haemoblasts undergoing high dose chemotherapy and hematopoietic cell transplantation. The study aims to understand the relationship between cancer treatments and the increased risk of cardiotoxicity, which can lead to severe cardiovascular diseases. By evaluating these diagnostic methods, the research seeks to identify patients at higher risk for cardiovascular issues post-treatment and potentially guide interventions to mitigate these risks.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who are scheduled to receive high dose chemotherapy and hematopoietic cell transplantation.
Not a fit: Patients who refuse participation in the study will not benefit from the findings or interventions proposed.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and prevention strategies for cardiovascular complications in cancer patients receiving high dose chemotherapy.
How similar studies have performed: Other studies have indicated a connection between hematopoietic cell transplantation and increased cardiovascular risk, suggesting that this approach is relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject being over 18 yers of age * Subject expected for high dose chemotherapy and hematopoietic cell transplantation Exclusion Criteria: * Subject's refusal
Where this trial is running
Moscow
- Sechenov University — Moscow, Russian Federation (Recruiting)
Study contacts
- Principal investigator: Nadezhda A. Potemkina — Sechenov University
- Study coordinator: Maria G. Poltavskaya, PhD
- Email: m.poltavskaya@yandex.ru
- Phone: +7 (916) 617-84-30
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.